NasdaqGS:RIGLBiotechs
Rigel Pharmaceuticals (RIGL): Valuation Insights After Raised 2025 Guidance and Q3 Performance
Rigel Pharmaceuticals (RIGL) raised its 2025 revenue guidance to $285 million to $290 million after reporting strong third-quarter earnings and record net product sales. Investors are taking notice as the company signals confidence in its outlook.
See our latest analysis for Rigel Pharmaceuticals.
After lifting its guidance and reporting robust Q3 results, Rigel’s stock has shown powerful momentum, with a 22.4% one-month share price return and an impressive 103% share price surge...